Numares Health AG, a Regensburg, Germany-based provider of a fully automated in-vitro diagnostics platform, received up to €40m in funding.
The European Investment Bank provided un up to €20m quasi equity financing for further research and development. Existing investors will contribute a complementary €20m for marketing investments to achieve mass commercialization of the proprietary technology products in the EU and U.S.
Led by CEO Winton Gibbons, Numares Health analyzes biomarker constellations with advanced use of nuclear magnetic resonance and artificial intelligence to improve diagnostics. The company has developed a fully automated in-vitro diagnostics platform, the AXINON System, which aims to improve the quality of diagnosing chronic diseases of the kidney, heart and liver, as well as cancer and multiple sclerosis. The system combines nuclear magnetic resonance (NMR) and artificial intelligence to collect and analyze metabolomic data from blood or urine samples. Instead of focusing on a single biomarker, Numares uses NMR to evaluate groups of metabolites, called “metabolite constellations,” that are analyzed by machine learning.
Several major U.S. laboratories are already using this chemical-free technology.
FinSMEs
21/12/2022